Topline
GSK and Vir announced on Wednesday that sotrovimab, a monoclonal antibody used in the treatment of Covid-19 that the two companies developed together, has been granted Emergency Use Authorization by the U.S. FDA.
Registered nurse treats coronavirus patient with Bamlanivimab, a monoclonal antibody.
Boston Globe via Getty Images
Key Facts
Sotrovimab was authorized for use in adults and children over 12 who are at high risk of developing severe Covid-19 due to age, medical history or other factors.
The drug is given to people before they are hospitalized, and led to an 85% reduction in hospitalizations and death among patients with Covid-19.
This is the third monoclonal antibody therapy that has been granted an EUA, following drugs from Regeneron and Lilly.
The FDA says that the GSK/Vir antibody remains effective against known Covid-19 variants that originated in the U.K., South Africa,…